NEW YORK (GenomeWeb News) – Digilab will market Axela's instruments in the US under an agreement announced today.
The deal calls for Digilab to market new versions of Toronto-based Axela's proprietary flow-through technologies, the Ziplex system and the dotLab mX system.
The Ziplex system is for gene and protein expression analysis and uses porous array technology to "fully automate hybridization and binding, washing, imaging, and data analysis without operator intervention," the two companies said in a statement.
The dotLab mX platform uses diffractive optics technology and label-free sensing to perform real-time immunoassay directly in complex samples, they added.
According to Joe Griffin, president of Digilab, based in Holliston, Mass., the next step in many of its proteomic and genomic customers' research is the validation of biomarker panels.
"By partnering with Axela, we can offer complete solutions from discovery to routine analysis, across a broad range of multiplex requirement," he said in a statement. "As part of the rapidly growing biomarker segment, we see product and application synergies in academic and clinical research, pharmaceutical discovery, and diagnostic development laboratories."
Financial and other terms of the deal were not disclosed.